<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="editorial" dtd-version="2.3" xml:lang="EN">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher-id">DIJ</journal-id>
         <journal-id journal-id-type="hwp">spdij</journal-id>
         <journal-title>Drug Information Journal</journal-title>
         <issn pub-type="ppub">0092-8615</issn>
         <publisher>
            <publisher-name>SAGE Publications</publisher-name>
            <publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="doi">10.1177/0092861512456285</article-id>
         <article-id pub-id-type="publisher-id">10.1177_0092861512456285</article-id>
         <article-categories>
            <subj-group subj-group-type="heading">
               <subject>Letter to the Editor</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>Mathematical Derivation of Therapeutic Index Based on hERG IC<sub>50</sub> Taking Into Account Fraction Unbound in Plasma and Clinical C<sub>max</sub>
            </article-title>
         </title-group>
         <contrib-group>
            <contrib contrib-type="author" corresp="yes" xlink:type="simple">
               <name name-style="western">
                  <surname>Fryer</surname>
                  <given-names>Ryan M.</given-names>
               </name>
               <degrees>PhD</degrees>
               <xref ref-type="aff" rid="aff1-0092861512456285">1</xref>
               <xref ref-type="corresp" rid="corresp1-0092861512456285"/>
            </contrib>
            <aff id="aff1-0092861512456285">
               <label>1</label>Department of Cardiometabolic Disease Research, Boehringer-Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA </aff>
         </contrib-group>
         <author-notes>
            <corresp id="corresp1-0092861512456285">Ryan M. Fryer, PhD, Boehringer-Ingelheim Pharmaceuticals Inc, 900 Ridgebury Road, Ridgefield, CT 06877, USA Email: <email xlink:type="simple">ryan.fryer@boehringer-ingelheim.com</email>
            </corresp>
         </author-notes>
         <pub-date pub-type="epub-ppub">
            <month>9</month>
            <year>2012</year>
         </pub-date>
         <volume>46</volume>
         <issue>5</issue>
         <fpage>519</fpage>
         <lpage>520</lpage>
         <permissions>
            <copyright-statement>© The Author(s) 2012</copyright-statement>
            <copyright-year>2012</copyright-year>
            <copyright-holder content-type="society">Drug Information Association</copyright-holder>
         </permissions>
      </article-meta>
   </front>
   <body>
      <p>It is accepted that hERG IC<sub>50</sub> values under manual patch conditions are reasonable surrogate predictors of QT prolongation in vivo, including in humans.  In this regard, Redfern et al<sup>
            <xref ref-type="bibr" rid="bibr1-0092861512456285">1</xref>
         </sup> have offered some guidelines regarding what might be deemed an appropriate therapeutic index (TI) to mitigate the risk of hERG-mediated arrhythmias for clinical candidates.  Regardless of the actual TI desired, there is, at times, a degree of confusion regarding how to calculate this value given the different units oftentimes ascribed to an IC<sub>50</sub> value versus those used to reference drug plasma concentrations. Moreover, how to account for free plasma concentrations (also referred to as fraction unbound or free fraction), which represents the amount of circulating compound that is biologically active (eg, not bound to albumin or other blood proteins), might not be obvious to the interested clinician.  Thus, offered below is a short primer to the topic that uses haloperidol as an example and makes the following assumptions: (1) the compound is 92% plasma protein bound in humans,<sup>
            <xref ref-type="bibr" rid="bibr2-0092861512456285">2</xref>
         </sup> (2) the hERG IC<sub>50</sub> value = 0.025 μM,<sup>
            <xref ref-type="bibr" rid="bibr3-0092861512456285">3</xref>
         </sup> and (3) the human clinical C<sub>max</sub> is approximately 25 ng/mL.<sup>
            <xref ref-type="bibr" rid="bibr2-0092861512456285">2</xref>
         </sup>
      </p>
      <p>First, plasma drug concentrations normally expressed in ng/mL or μg/mL need to be converted into a molar value because most hERG IC<sub>50</sub> values are also expressed in μM (hint: μM and μM/L can be considered equivalent units).  If the plasma concentration of haloperidol at C<sub>max</sub> = 25 ng/mL, the molar value can be easily calculated using the molecular weight (MW = 375.85) as the following: 25 ng/mL ÷ 375.85 = 0.0665 μM (66.5 nM).  The MW of most compounds can be queried online; an important consideration is to ensure that the MW used in the calculation does not include the weight of any associated salt (eg, haloperidol decanoate has an MW of 530.11, reflecting the addition of the decanoic acid), as the salt generally dissociates upon entry into the blood and is not measured in the plasma.  Thus, the equation boils down to μM = ng/mL ÷ free base MW, or μM = (μg/mL ÷ free base MW) * 1000.</p>
      <p>If one wishes to establish a TI relative to a hERG IC<sub>50</sub> based on total drug concentrations in the blood, simply divide the hERG IC<sub>50</sub> value (0.025 μM) by the C<sub>max</sub> blood concentration also expressed in μM: 0.025 μM / 0.0665 μM = TI &lt; 1X.  If, however, one wishes to establish a TI based on free plasma concentrations, the degree of plasma protein binding must be built into the calculation.  In the case of haloperidol that is 92% plasma protein bound (8% free, or 0.08), the free concentration at C<sub>max</sub> = 0.0665 μM * 0.08 = 0.005 μM (5 nM).  In this example, the TI relative to a hERG IC<sub>50</sub> based on fraction unbound = 0.025 μM / 0.005 μM = 5X, a margin consistent with a category 3 drug (as defined by Redfern et al<sup>
            <xref ref-type="bibr" rid="bibr1-0092861512456285">1</xref>
         </sup>) with a measurable incidence of torsades de pointes in humans and a margin below that deemed acceptable for most new chemical entities entering first-in-human clinical trials for nondebilitating diseases. </p>
      <p>Fitting all of the pieces together, a TI relative to the hERG IC<sub>50</sub> and unbound plasma concentrations at C<sub>max</sub> can be calculated as TI = μM hERG IC<sub>50</sub> / [(ng/mL at C<sub>max</sub> ÷ free base MW) * free fraction].</p>
   </body>
   <back>
      <fn-group>
         <fn fn-type="conflict" id="fn1-0092861512456285">
            <label>Declaration of Conflicting Interests</label>
            <p>The author declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: The author is employed by Boehringer-Ingelheim Pharmaceuticals Inc.</p>
         </fn>
         <fn fn-type="financial-disclosure" id="fn2-0092861512456285">
            <label>Funding</label>
            <p>The author received no financial support for the research, authorship, and/or publication of this article. </p>
         </fn>
      </fn-group>
      <ref-list>
         <title>References</title>
         <ref id="bibr1-0092861512456285">
            <label>1</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Redfern</surname>
                     <given-names>WS</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Carlsson</surname>
                     <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Davis</surname>
                     <given-names>AS</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development</article-title>. <source>Cardiovasc Res</source>. <year>2003</year>;<volume>58</volume>(<issue>1</issue>):<fpage>32</fpage>–<lpage>45</lpage>.</citation>
         </ref>
         <ref id="bibr2-0092861512456285">
            <label>2</label>
            <citation citation-type="book" xlink:type="simple">
               <article-title>Haloperidol decanoate 50 and 100 mg/mL injection [label]</article-title>. <publisher-loc>Beerse, Belgium</publisher-loc>: <publisher-name>Janssen Pharmaceutica N.V</publisher-name>.; <year>2011</year>. </citation>
         </ref>
         <ref id="bibr3-0092861512456285">
            <label>3</label>
            <citation citation-type="book" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Kirsch</surname>
                     <given-names>GE</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Trepakova</surname>
                     <given-names>ES</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Brimecombe</surname>
                     <given-names>JC</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern</article-title>. <source>J Pharmacol Toxicol Methods</source>. <year>2004</year>;<volume>50</volume>(<issue>2</issue>):<fpage>93</fpage>–<lpage>101</lpage>.</citation>
         </ref>
      </ref-list>
   </back>
</article>